These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 22696054)
1. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054 [TBL] [Abstract][Full Text] [Related]
2. The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. Charles J; Chaperot L; Revol B; Baudin M; Mouret S; Hamon A; Leccia MT; Plumas J; Aspord C Pigment Cell Melanoma Res; 2018 Jan; 31(1):82-94. PubMed ID: 28741900 [TBL] [Abstract][Full Text] [Related]
3. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
5. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. Aspord C; Charles J; Leccia MT; Laurin D; Richard MJ; Chaperot L; Plumas J PLoS One; 2010 May; 5(5):e10458. PubMed ID: 20454561 [TBL] [Abstract][Full Text] [Related]
6. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells. Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560 [TBL] [Abstract][Full Text] [Related]
7. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
9. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537 [TBL] [Abstract][Full Text] [Related]
10. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033 [TBL] [Abstract][Full Text] [Related]
12. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772 [TBL] [Abstract][Full Text] [Related]
13. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Aspord C; Laurin D; Richard MJ; Vie H; Chaperot L; Plumas J Am J Transplant; 2011 Dec; 11(12):2613-26. PubMed ID: 21883919 [TBL] [Abstract][Full Text] [Related]
14. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961 [TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. Kageshita T; Kawakami Y; Ono T J Dermatol Sci; 2001 Jan; 25(1):36-44. PubMed ID: 11154862 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843 [TBL] [Abstract][Full Text] [Related]
19. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553 [TBL] [Abstract][Full Text] [Related]
20. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]